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ORIGINAL ARTICLE
Introduction: Integrated care pathways (ICPs) have been proposed 
as effective strategies for quality improvement. To date, limited data 
are available that detail the methodology to design an optimal care 
pathway for patients with non–small-cell lung cancer (NSCLC). The 
main aim of this study was to assess the quality of health care deliv-
ered to lung cancer patients referred to a hub university hospital.
Methods: All professionals involved with the management of 
NSCLC patients, in cooperation with health care researchers, identi-
fied 11 quality indicators and associated benchmarks. These were 
used to estimate the quality and efficiency of health care delivered to 
a cohort of 175 NSCLC patients.
Results: The gap between “desired” and “actual” performance has 
been measured by benchmarking current practice against key qual-
ity indicators. Diagnostic workup, multidisciplinary team care and 
medical treatment of advanced disease have emerged as areas of 
good performance. Conversely, the management of early-stage dis-
ease offers room for improvement, in terms of both accuracy of nodal 
staging and surgical timeliness.
Conclusions: Analyzing the process of caring for NSCLC patients is 
feasible and offers room for improvement. Acquired knowledge may 
be shared with hospital administrators, guide the revision of ICPs, 
and enable the delivery of consistent, high-quality clinical standards.
Key Words: Health care indicators, Integrated care pathways, 
Non–small-cell lung cancer, Quality improvement.
(J Thorac Oncol. 2012;7: 1283–1290)
Lung cancer is the most common cancer and the leading cause of cancer death in men worldwide. In women, it is 
the fourth most frequent cancer and the second leading cause 
of cancer death.1 The management of patients with suspected 
or known lung cancer is becoming increasingly complex, 
because state-of-the-art care requires input and coordination 
among many different specialty competencies.
So far, limited data exist detailing how these patients 
flow through the health care system, the sequence of activi-
ties performed, and the delays and barriers that may interfere 
with the patient journey, from the point of diagnosis onward. 
Inadequate literature exists describing well-tested methodolo-
gies to develop an optimum care plan for this specific patient 
group. The wide availability of evidence-based guidelines and 
the institution of multidisciplinary teams and meetings has 
improved both clinical effectiveness and service coordination 
among hospital departments, but does not automatically trans-
late into the development of leading-edge care models.2
Integrated care pathways (ICPs) are structured, multi-
disciplinary care plans for a specific clinical condition, which 
describe the tasks to be pursued,  their timing, sequence, 
and the professionals and departments involved.3 ICPs are 
emerging as strategies of improvement from the perspective 
of professionals, organizations, and patients, and they may 
encourage the enforcement of clinical guidelines in routine 
practice. They provide a means to improve multidisciplinary 
communication and care planning, to optimize the safety 
and quality of care, and to increase patient satisfaction. This 
approach also allows for systematic collection and clinical 
data extraction for audit purposes, promoting the identifica-
tion of research and development questions.4 ICPs are particu-
larly meaningful in teaching hospitals, because they support 
a continuous process for quality improvement, through the 
adoption of innovations coming from research and teaching.5
The selection of proper quality-of-care indicators is a 
critical step in the development of ICPs. Quality indicators 
have been defined as “measurable elements of practice per-
formance for which there is evidence or consensus that they 
can assess the quality of care.”6 In other words, they represent 
milestones against which to measure a patient’s progress along 
a care pathway by comparing them with literature-derived 
standards or stakeholder values. Once developed, ICPs should 
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be shared and supported by hospital administrators, reflecting 
the organization’s aims and philosophy, and being delivered 
within the framework of its strategic plan.
The aim of this study was to map the existing health 
care pathway of non–small-cell lung cancer (NSCLC) patients 
referred to the University Hospital of Udine from January 1, 
2008 to December 31, 2008; to use a number of selected, 
relevant indicators to measure overall process performance; 
and to identify opportunities for improvement and a model 
to guide the design of tailored ICPs. The ultimate aim is 
the construction of a directional dashboard allowing for the 
routine monitoring of the hospital performance as a result of 
the introduction of ICPs.
MATERIALS AND METHODS
This study applied a methodological framework derived 
primarily from the work by Ouwens et al.,7 although its retro-
spective nature entailed less patient involvement in the shar-
ing of performance indicators. The study was conducted in a 
teaching institution that is a result of the merger of a regional 
hospital and a university hospital. With almost 1000 beds, this 
hospital consists of 14 integrated departments, covers nearly 
all major specialties, and is a regional referral center serving 
a population of approximately 1 million inhabitants in the 
northeast of Italy.
This study project was developed collecting data and 
information from both expert panels and the hospital informa-
tion system. Two working groups were established. The first 
was a steering committee, consisting of both professionals and 
health care researchers who were involved in study planning 
and operational organization, performed a critical data evalu-
ation, and guided the tailored revision of current clinical path-
ways. The second was a professional focus group of specialists 
involved in the management of NSCLC patients, i.e., medical 
oncologists, pulmonologists, radiologists, thoracic surgeons, 
pathologists, nuclear medicine physicians, and radiothera-
pists. As a multidisciplinary group, these professionals have 
met on a regular basis for 20 years to discuss selected cases, 
share information, and jointly agree on the best management 
plan for an individual patient. Health care researchers from 
Bocconi University, Milan, were invited to join these meetings 
to lead the focus group in an additional final session.
The specific contribution offered by the team of health 
care experts mainly concerned the methodological approach 
to the research. Indeed, health care researchers helped clini-
cians to identify current practices and processes and to map 
them in a flowchart, i.e., a graph using codified symbols to 
depict the order of steps in a particular process. Furthermore, 
they supported the selection and operalization of quality or 
performance indicators.
The following activities were carried out by the focus 
group:
1. Mapping of the existing local care process. Group mem-
bers graphically depicted in an organizational map the 
order of steps in the current care pathway of NSCLC 
patients, from the first hospital visit to the follow-up 
phase. Because of the need for different management 
strategies, separate flowcharts were drawn up for patients 
with early, locally advanced, and metastatic disease, 
respectively. The map aimed to detail the temporal 
sequence of care and activities performed, the role and 
responsibilities of each unit involved, and the relation-
ships between different individuals and departments. The 
care process was divided into three phases—diagnosis 
and staging, treatment, and follow-up—to improve the 
level of detail.
2. Selection of quality-of-care indicators. Among 21 ini-
tially available indicators, 11 were selected based on 
three main properties, i.e., validity—the ability to assess 
both clinical and organizational aspects of current care, 
feasibility of automatic data extraction from the hospital 
information system, and reliability—the reproducibility 
of measurement over time. An additional reason for their 
selection was the availability of a corresponding bench-
mark, which was derived from previous studies, interna-
tional professional guidelines, ICP-specific literature, or 
according to the experts’ opinion. Indeed, because of the 
limited availability of evidence on organizational stan-
dards, related indicators and benchmarks were developed 
using group-facilitation techniques designed to explore 
the level of consensus among a group of experts and to 
aggregate judgments into refined agreed opinions.6
3. A retrospective analysis of the quality level of exist-
ing care pathways. One hundred and seventy-five 
NSCLC patients, who were referred consecutively to the 
Department of Oncology of Udine University Hospital 
from January 1 to December 31, 2008, were identified. 
Patient age, sex, pathological diagnosis, disease stage, 
and performance status were recorded. Data were col-
lected on all the diagnostic, staging and treatment proce-
dures performed. The care processes were reviewed from 
3 months before diagnosis to 12 months after, and their 
quality level assessed by applying selected indicators.
RESULTS
Figure 1 illustrates an example of process mapping, 
showing the management flowchart for IIIA-N2 patients. 
As previously mentioned, separate diagrams were drawn for 
patients with disease stage I, II and selected IIIA; IIIA-N2; 
selected IIIB (i.e., no pleural effusion and no supraclavicular 
node involvement); and IIIB-IV (American Joint Committee 
on Cancer tumor, node, metastasis (TNM) staging system, 6th 
edition, 2002).7 Diagnosis, treatment by stage, and follow-up 
phases were analyzed separately. Distinct graphs were also 
drawn to represent the follow-up of patients with active versus 
no evidence of disease, respectively.
As shown, common and predictable events are arranged 
on two axes. The vertical axis represents the temporal sequence 
of health activities and their causal relationship. Involved hos-
pital units and the relationships among different individuals 
and departments are plotted on the horizontal axis. Codified 
symbols are used to indicate the starting and ending points of 
the pathway, and clinical episodes, critical decision-making 
moments, and document management, respectively (Fig. 1).
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Once developed, the map may be analyzed in light of 
selected indicators to identify problem areas such as duplica-
tion, delays, service shortfalls and nonadherence to guidelines. 
A list of selected indicators and their description is provided 
in Table 1. Associated benchmarks were derived from specific 
literature,8–18 if available, or produced by consensus among the 
focus-group experts.
With this premise, the care pathway of 175 NSCLC 
patients who were admitted to the University Hospital of 
Udine over the study period was retrospectively reviewed. 
Main patient characteristics are summarized in Table 2. 
Briefly, 71% were men, the mean age was 68 years, and most 
(80%) were classified as having locally advanced or metastatic 
disease.
The information systems of both the whole hospi-
tal and of the oncology unit, which provides a full suite of 
department-specific information, were queried to retrieve 
critical information. Selected indicators were applied to 
measure the quality of health care delivered to the study 
population (Table 1).
The median time from first admission to the Pulmonary 
Unit (PU) to the first visit with a medical oncologist (indicators 
1a–1b) was different for patients with stage I–IIIA disease 
(n = 29; 84 days) and those with advanced disease (n = 85; 28 
days), corresponding to the upper and lower bounds of their 
respective benchmark time intervals.8,11
Timeliness of cancer diagnosis was measured as median 
time from both first bronchoscopy to pathological diagnosis 
(indicator 3; n = 131) and from first admission to the PU to 
pathological diagnosis (indicator 4; n = 116). Results com-
pared well against external benchmarks, with median times of 
5 versus 7 days and 16 versus 15 to 20 days, respectively.10–14
The median time from computed tomography-posi-
tron emission tomography (CT-PET) to surgery in poten-
tially resectable patients (indicator 2; n = 25) was within the 
benchmark values (23 days, interval values 14–28 days),12–15 
whereas scores of overall surgical timeliness—measured 
as the median time from pathological diagnosis to surgery 
(indicator 5a; n = 19)—performed poorly against literature 
benchmarks (50 versus 28–35 days).8,11,15 As for the medical 
FIGURE 1.  Flowchart of the management steps of stage IIIA-N2 patients demonstrating an example of the local care process. 
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treatment of patients with advanced disease, the median time 
from pathological diagnosis to chemotherapy (indicator 5b; 
n = 104) was slightly higher than the benchmark upper value 
(26 days versus benchmark interval values of 14–21 days).8,11,15
A CT-PET was performed within 3 months before radi-
cal surgery in 23 of 37 patients with early disease. Of three 
patients with positive mediastinal nodes on CT-PET, none 
underwent invasive nodal staging. Conversely, a mediasti-
noscopy was performed in one patient despite negative PET 
findings. Overall, 3% of potential surgery candidates under-
went a cervical mediastinoscopy after a CT-PET (indicator 
6).8,12 The proportion of patients receiving a multidisciplinary 
evaluation (indicator 7; n = 175) seemed well aligned to the 
benchmark,8,12 as well as the yearly number of consultations 
for each patient started on medical treatment (indicator 10; 
n = 104).17
Finally, a high-quality level was detected when 
indicators of appropriate medical treatment (indicators 8, 9, 
and 11) were measured. No patients with Eastern Cooperative 
Oncology Group performance status ≥ 2 (indicator 8; n = 9) 
received a two-drug combination.13,14,16 All patients received 
a maximum of three treatment lines (indicator 9; n = 104), 
corresponding to the benchmark value;13,14,16 only 16% of 
patients (benchmark value, 20%) received an active medical 
treatment within 30 days of death (indicator 11; n = 104).18
DISCUSSION
International health systems have been under significant 
pressure in recent years, facing a precarious balance between 
resource supply and service demand. Cancer care systems are 
particularly challenged by additional factors, including an 
aging and growing population, increasing cost of drugs and 
technology, and projected workforce shortages.19 Sullivan 
et al.20 detail how urgent solutions are needed, including a 
reengineering process of the macroeconomic basis of can-
cer costs, a transparent regulatory system and, importantly, a 
greater education of policy makers. The US Congress seems 
to have taken up the challenge: Title VIII of the American 
TABLE 1.  Selected quality indicators and corresponding benchmarks.
Indicator
N of 
patients
Median/ 
percentage
Benchmark/
benchmark 
interval values
1a - Time from 1st admission to the Pulmonary Unit to 1st 
oncology visit (stage I-IIIA), days
29 84 56–84 (B)
1b - Time from 1st admission to the Pulmonary Unit to 1st 
oncology visit (stage IIIB-IV), days
85 28 28–42 (B) 
2 - Time from CT-PET to surgery, days 25 23 14–28 (B) 
3 - Time from the 1st invasive diagnostic procedure to 
pathological diagnosis, days
131 5 7 (B) 
4 - Time from 1st admission to the Pulmonary Unit to 
pathological diagnosis, days
116 16 15–20 (A) 
5a - Time from pathological diagnosis to surgery, days 19 50 28–35 (B) 
5b - Time from pathological diagnosis to chemotherapy, days 104 26 14–21 (B) 
6 - Patients who underwent a cervical mediastinoscopy 
following a CT-PET before surgery, %
37 3 (%) 80–100 (A) 
7 - Patients for whom there was evidence of a multidisciplinary 
evaluation, %
175 50 (%) 55 (A) 
8 - ECOG PS > 1 patients receiving a doublet chemotherapy, % 9 0 (%) 0 (A) 
9 - Patients receiving more than three treatment lines, % 104 0 (%) 0 (A) 
10 - Per-patient yearly number of oncology visits, average 
number
104 18 16 (A) 
11 - Patients who received an active medical treatment within 
30 days of death, %
104 16 (%) 20 (B) 
PS: performance status
(A) According to evidence based guidelines or to ICP-specific literature; (B) According to expert consensus.
TABLE 2. Main patients’ characteristics.
Characteristics N = 175
Range/
Percentage
Average age* (years) 68 40–88
Male/Female 125/50 71%/29%
Disease stage* 
 I 19 11%
 II 16 9%
 III 44 25%
 IV 96 55%
First treatment
 Surgery 40 23%
 Radiation therapy 6 3%
 Chemotherapy 89 51%
 No treatment 29 17%
 Not applicable# 11 6%
*At first medical oncology visit
#First treatment performed at another center
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Recovery and Reinvestment Act of 2009 authorizes the expen-
diture of $1.1 billion to conduct research comparing “clinical 
outcomes, effectiveness, and appropriateness of items, ser-
vices, and procedures” related to the world of health care.21 
Several reports exist of significant benefits associated with 
the introduction of ICPs into clinical practice,4 including an 
opportunity for health care cost reductions.22
Cancer patients frequently experience fragmented 
health care journeys and suffer from a lack of continuity 
of care.23 Their management is often planned only as far as 
the next consultation, rather than being scheduled for the 
whole sequence of events that are foreseen from the point of 
diagnosis, with consequent higher costs and loss in time and 
efficiency.24 Integrated disease management has emerged as 
an innovative strategy to deliver high-quality health care 
and align affordability with principles of equitable and uni-
versal access.4
Our study shows the feasibility of process mapping as 
a tool to elicit the delivery of care at every step of the lung 
cancer patients’ journey in a hub university hospital; to moni-
tor its alignment to international guidelines; and to develop 
proposals for a revised pathway, ensuring services are deliv-
ered in a coherent and timely manner. In our experience, such 
activity also allows cancer specialists to acknowledge the pro-
fessional skills acquired as a multidisciplinary group and the 
emergence of both a clinical and an organizational know-how. 
Together with process mapping, the identification and selec-
tion of proper quality indicators is an essential step toward 
drafting a revised care pathway, because quantifying adher-
ence to performance indicators may provide the foundation 
for quality improvement.22,25
Our internal benchmarking process has highlighted the 
management of NSCLC patients with early disease as the 
most critical area, in both clinical and organizational dimen-
sions. Because this patient group may have a better long-term 
prognosis, maximum effort should be made to ensure them the 
delivery of ready and well-coordinated services, despite the 
high complexity of procedure requirements. In our analysis, 
the median time from first admission to the PU of patients 
with early disease to the first visit with a medical oncolo-
gist (indicator 1a)—which may influence a patient’s chance 
of receiving adjuvant treatment—was 84 days, corresponding 
to the upper bound of the benchmark time interval. As the 
median time from CT-PET to surgery (indicator 2) seems to be 
well aligned to the benchmark, one could speculate that most 
organizational problems correlate with delays in the diagnos-
tic/staging procedures preceding PET (Fig. 2). Another pos-
sible explanation is a time delay between surgery and referral 
to oncology consultation. In a retrospective review, 50% of 
NSCLC patients who underwent radical surgery were referred 
to medical oncology for consideration of adjuvant chemother-
apy. Where stated, reasons for not referring were as follows: 
postoperative complications (n = 15), comorbidities (n = 10), 
patient refusal (n = 9), surgeon’s decision (n = 6), disease pro-
gression (n = 3), advanced age (n = 3), other cancer (n = 1), 
and time delay believed too long (n = 1).26 These findings 
emphasize that previously reported delays or surgeons’ nega-
tive attitude27 toward the benefits of adjuvant chemotherapy 
may still persist despite multidisciplinary meetings and pub-
lished guidelines on waiting-time targets.28
Surgical timeliness (indicator 5a) represents a further 
critical area. This may be associated both with the process 
weaknesses highlighted in Figure 2 and with a disproportion 
between the number of skilled surgeons and operating ses-
sions and the increase in patient volume.
Results for indicator 6 suggest that the surgical jour-
ney of lung cancer patients through the hospital environment 
also suffers from a lack of appropriateness, with no surgical 
candidate with positive PET findings undergoing mediasti-
noscopy. Accurate mediastinal staging is the hallmark of a 
sound thoracic oncology program and represents the primary 
tool for making treatment decisions for NSCLC patients.29 
Current guidelines advocate mediastinoscopy as the gold 
standard staging technique in patients with positive CT/
PET findings. In a retrospective study of NSCLC patients 
having undergone single (CT only), bi- (CT and PET or CT 
and mediastinoscopy), or tri-modality (CT, PET, and medi-
astinoscopy) staging, the significant increase over time in 
the use of bi- and tri-modality staging seemed to be mostly 
the consequence of a growing use of PET, whereas invasive 
staging decreased from 9% to 8% (p trend 0.005). Recent 
scientific evidence that a high negative predictive PET value 
reduces the need for invasive staging is a possible explana-
tion of such trends, but alternative reasons may be a limited 
FIGURE 2.  Time interval from first 
admission to the pulmonary unit of 
patients with early disease to surgery 
demonstrating areas of weakness and 
room for improvement. PU, pulmo-
nary unit; FBS, fibrobronchoscopy.
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access to adequately trained thoracic surgeons, or the false 
perception that PET may be a proper and safer staging sub-
stitute.30 A relative paucity of experienced surgeons and of 
available surgical sessions have been identified by our inter-
nal auditing as main reasons for the poor performance of 
indicator 6.
Finally, some opportunities for improvement may be 
identified in the timeliness of both staging procedures in 
patients with advanced disease (indicator 5b), and of cancer 
diagnosis (indicator 3). Indeed, despite the observation of 
short waiting times from first bronchoscopy to tumor diag-
nosis, the authors believe that the onsite assessment of bron-
choscopy samples by a cytopathologist might significantly 
improve the diagnostic yield, reducing the rate of specimen 
inadequacy and the need for repeat examinations,  as well as 
costs and patient discomfort.31
This study has demonstrated that good performance 
levels have been achieved in the area of medical treatment 
of patients with advanced disease (indicators 8, 9, and 11). 
These results gain particular importance in terms of quality 
assurance, because corresponding indicators are based on 
level 1 evidence and show high consistency across national 
and international guidelines.
It is worth noting that the proportion of NSCLC patients 
for which there was retrospective evidence of a multidisci-
plinary evaluation was near optimal (50%, versus a bench-
mark value of 55% —indicator 7). This is an essential finding 
because multidisciplinary team meetings are widely accepted 
as a means to significantly impact on the quality of patient 
care by improving communication flow among team mem-
bers; optimizing management strategies, waiting times and 
cost effectiveness; providing opportunities for education and 
learning to its members; and fostering the identification of 
suitable patients for inclusion in clinical trials.32 However, 
limited evidence exists correlating multidisciplinary teams’ 
management with improved clinical outcomes, particularly 
with survival.33
Indicator 10, which refers to the number of per-patient 
yearly consultations, seems slightly higher than the corre-
sponding benchmark value. However, the number was derived 
from a database also including breast and colorectal cancer 
patients, who are less frequently diagnosed with advanced 
disease and may be assumed to require fewer medical reevalu-
ations. The yearly number of per-patient visits is an exquisite 
organizational indicator; indeed, we have previously demon-
strated that it represents the main variable of a simple model 
allowing the forecast of the human resource needs of a cancer 
unit. It may be argued that the identification of leading deter-
minants of health care expenditures other than drug costs may 
be important in setting priorities for resource allocation and in 
revealing significant opportunities for cost saving.17
This study presents some limitations. First, it is a ret-
rospective review covering a limited 12-month period and 
including a relatively small sample of 175 patients, although 
these figures are not so far from those presented by Ouwens 
et al.,8 with 276 newly diagnosed patients analyzed during a 
6-month period.
Second, some robust indicators of the quality of care, 
such as perioperative mortality, postoperative length of stay, 
or the proportion of surgical patients with stage II–III NSCLC 
who were administered adjuvant chemotherapy, are lacking. 
Unfortunately, the reliability and feasibility of automatic 
extraction of specific data may be compromised by some 
level of uncertainty in disease and/or procedure codes within 
the hospital information system. As for the number of patients 
undergoing adjuvant medical treatment after radical surgery, 
the analysis was further hampered by the fact that, even though 
our Thoracic Surgery Unit is a regional referral center, several 
patients may be subsequently treated and followed up in local 
cancer units other than ours. Still, these drawbacks may also 
be seen as an opportunity for improvement, contributing to the 
identification of system inadequacies and unreliable behavior, 
and stimulating the search for solutions.
Third, this is a single-center study, whereas an accurate 
assessment of quality indicators probably requires pooling 
data from multiple sources across a broad region. However, it 
should be considered that our hospital represents the region’s 
leading medical center and serves as the referral facility for 
the vast majority of lung cancer patients of this geographical 
area. Rather, in an ongoing study we are making an effort to 
include in the analysis all phases of the continuum of care, 
from initial diagnosis suspicion to post-treatment/postdis-
charge care. As shown by Lo et al.10 some benefit may arise 
from focusing on the whole continuum of care, such as an 
earlier disease diagnosis.
In any case, it should be pointed out that the visit to 
a pulmonologist represents the first step of the care pathway 
for nearly all the lung cancer patients who are referred to our 
university hospital. This direct-access modality has been the 
item of an official meeting between hospital representatives 
and local general practitioners, and is regulated by a formal 
agreement document.
In general, at each phase of their journey, patients 
encounter a new set of clinicians: general practitioners 
during the prevention and screening phases; pulmonologists, 
radiologists, and surgeons in the diagnostic phase; and 
oncologists, radiation oncologists, and surgeons at the time 
of treatment. After treatment, patients often return to primary-
care settings and encounter specialists in rehabilitation and 
palliative care.34 Quality of care may be impaired by both 
breakdowns in specific types of care delivered to patients 
at different points of their history and during the transitions 
between these types of care.35
Finally, our study focused on professional- and organiza-
tional-quality indicators, with less attention posed on patients’ 
perspective and no direct involvement of patients or their care-
givers, a factor that the specific literature identifies as sub-
stantial for a comprehensive development of ICPs.36 Patient 
recommendations should be incorporated into evidence-based 
clinical guidelines for a patient-centered management of can-
cer and translated into quality indicators.37 Measuring the 
level of patient centeredness of cancer care will be a primary 
aim of a future prospective study currently being planned at 
our institution.
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The strengths of this study lie mainly in its level of 
analysis. Indeed, for the first time the health care pathways 
of NSCLC patients have been distinguished and analyzed by 
stage, improving the level of detail and easing the identifi-
cation of specific problem areas, which may require differ-
ently targeted strategies of improvement. This study has been 
conducted in an almost fully computerized hospital, a feature 
which has expedited the identification of a suitable cohort of 
patients and assisted in the selection of indicators that might 
be easily retrieved from the hospital medical record system.
These projects—arising from the desire of further focus-
ing on clients’ needs—have the potential to exert a profound 
influence on the participants of multidisciplinary meetings; 
moreover, the presence of different professional figures, spe-
cifically management experts and researchers promotes the 
development of a new, interprofessional perspective, provid-
ing opportunities to learn and reflect critically on one’s own 
knowledge base.
Once key areas for improvement were identified and 
considerable time was spent to evaluate and select suggestions 
for change, focus-group members developed an amendment 
proposal to the existing care process. The document was sub-
mitted to and evaluated by the steering committee for ease 
of use, effectiveness, and final acceptance. It will soon enter 
into a negotiating process between physicians and health care 
executives for its official endorsement and adoption by the 
organization.
In conclusion, our study demonstrates that the intro-
duction of the general principles of ICP methodology in a 
teaching hospital is feasible and allows the assessment of the 
quality level of the health care delivered to a specific patient 
group/population. This knowledge may be shared with hos-
pital managers and executives with the aim of reengineering 
care delivery focusing on processes, people, and technologies.
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